Please ensure Javascript is enabled for purposes of website accessibility

Why Nevro Is Falling So Hard Today

By Eric Volkman – Aug 5, 2021 at 4:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A narrower-than-expected loss was about the only bright spot in the company's second-quarter results.

What happened

Specialty medical device maker Nevro (NVRO -5.66%) had an awful Thursday, with its shares collapsing by over 24% in late afternoon trading. Investors were punishing the company for a worse-than-expected second-quarter earnings report.

So what

In terms of headline numbers, Nevro's performance for the quarter was mixed. It earned $102.3 million in revenue, nearly double the $56.4 million it booked in the same period a year ago. However, the former didn't reach the collective analyst estimate of $104.5 million.

A person on a bed clutching their back in pain.

Image source: Getty Images.

The company, a healthcare device maker that specializes in pain-treatment solutions, did manage to narrow its net loss to $21.5 million ($0.62 per share) from Q2 2020's $41 million. That bettered the average prognosticator forecast of a $0.71-per-share deficit.

In its earnings release, Nevro quoted its CEO D. Keith Grossman as saying, "The recovery of procedural volumes in the pain market generally and the [spinal cord stimulation] market specifically has been slower than we anticipated, impacting not only Q2 revenues, but in the case of lower trial procedures, revenue in future months as well."

Now what

As a result, Nevro trimmed its guidance for the third quarter. It now believes it will post $90 million to $93 million in revenue, which is down on both a quarter-over-quarter (by at least 14%) and year-over-year (minimally 7%) basis. Adjusted earnings before interest, taxes, depreciation, and amortization, or EBITDA, will be in the red, from $10 million to $12 million. A net profit/loss estimate was not provided.

Due to the "lack of visibility around COVID-related recovery trends and timelines," the company has withdrawn its full-year outlook.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Nevro Stock Quote
Nevro
NVRO
$45.19 (-5.66%) $-2.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.